Low- and no-calorie ingredients are logical choices for those wishing to manage their weight. However, some people have concerns that sucralose may be linked to cancer.
Now, a comprehensive review of studies testing the safety and carcinogenicity of sucralose has confirmed that the artificial sweetener does not cause cancer and is safe to ingest.
"This latest review of sucralose studies should reassure those who choose sucralose and can be particularly useful to scientists and health-care professionals, who may be asked for information on low calorie sweetener safety," said lead author Colin Berry, Professor at the University of London in the UK.
These studies are designed to maximise the possibility of detecting potentially adverse effects, and as such, adverse outcomes are expected to occur at some point.
To that end, many of the studies observe the results of dosages hundreds to thousands of times greater than any reasonable level of consumption.
For example, the studies reviewed include observations on consumption of sucralose in quantities equivalent in sweetness to 74 to 495 pounds of sugar per day for an average weight (75 kg) adult.
In the studies reviewed, even when exposure levels were several orders of magnitude greater than the recommended ADI, sucralose did not demonstrate carcinogenic activity.
"Concerns are raised from time to time on what components of our lifestyle affect the rates of cancer," said Berry.
"Smoking and sunlight are on all our lists and obesity is beginning to be recognised as a major factor. So low calorie sweeteners, which are important to many in managing their weight, need to be examined carefully in terms of lifetime use," he added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
